Glaucoma treatment market to reach $3 billion by 2023: Report

The treatment market for glaucoma will rise in value from $2.4 billion in 2013 to around $3 billion by 2023 across the seven major markets (7MM) of the USA, France, Germany, Italy, Spain, UK, and Japan, representing a moderate overall compound annual growth rate (CAGR) of 2.4%.

Market research titled EpiCast Report: Glaucoma - Epidemiology Forecast to 2023 states that growth will be driven by the arrival of innovative first-in-class drugs, such as Aerie Pharmaceuticals’ (Nasdaq: AERI) Rhopressa/Roclatan (previously known as AMA0076), Bausch + Lomb’s Vesneo (latanoprostene bunod), and Inotek Pharmaceuticals’ (Nasdaq: ITEK) trabodenoson, and the introduction of additional fixed-dose combination (FDC) products, such as Santen Pharma’s Tapcom/Taptiqom tafluprost/timolol maleate and Alcon’s Simbrinza (brimonidine and brinzolamide), during the forecast period.

Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eye's optic nerve, resulting in progressive, irreversible vision loss. Glaucoma is one of the leading causes of blindness worldwide, especially in elderly people. Glaucoma is generally categorized as open-angle glaucoma (OAG), angle-closure glaucoma (ACG), secondary glaucoma, and congenital glaucoma. Other less common types of glaucoma include normal-tension glaucoma (NTG), pseudoexfoliation glaucoma, and pigmentary glaucoma (NEI, 2014b). Although there are many types of glaucoma, the two most important types are OAG and ACG, with OAG accounting for about 80-90% of all glaucoma cases (Mayo Clinic, 2014). OAG and ACG can be primary (primary open-angle glaucoma [POAG] and primary angle-closure glaucoma [PACG], respectively) or secondary, depending on the cause.